Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04620278

Genetic Investigation of Cancer Predisposition

Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Texas Health Science Center

San Antonio, Texas, 78229, United States

About this study

Genetic screening will be performed on DNA (and/or RNA) isolated from collected samples from affected individuals by whole exome sequencing or RNA sequencing using in-house pipeline to identify candidate sequence variants. These variants will be tested for segregation with the phenotype in other relatives (affected/unaffected). Candidate variants will be subjected to additional downstream analysis, to be guided by the actual type of gene/variant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any age
  • Meets at least ONE of the following:
  • Personal history (with documented diagnosis) of cancer before the age of 50
  • Personal history of more than one primary cancer
  • Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes
  • Documented diagnosis of a rare cancer AND family history of rare cancers that do not fit classical criteria of hereditary cancer syndromes
  • There is the same type of cancer in several generations of a family
  • Documented diagnosis of multicentric cancers (e.g bilateral cancers in paired organs, or multifocal cancers in single organs) that usually occur as single lesions when presented sporadically
  • Early onset cancer (before the age of 50, or breast cancer before age 45) AND family history of early onset cancer Capable of providing access to detailed medical records and family history of cancer

Exclusion criteria

  • Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation
  • Incarcerated

Treatment and study plan

DNA or RNA Sequencing

Genetic

Samples will be used for whole exome (DNA) or RNA sequencing

Primary outcomes

  1. Identification of Rare Genetic Variant

    Time frame: through study completion- approximately 6-12 months

    Genetic screen detects a mutation that is likely responsible for tumor development

  2. Identification of somatic (tumor only) mutation

    Time frame: through study completion- approximately 6-12 months

    Genetic screen detects a mutation that is likely responsible for tumor development

  3. Identification of Rare Genetic Variant in family members

    Time frame: through study completion- approximately 6-12 months

    Genetic screen detects a mutation that is likely responsible for tumor development

Secondary outcomes

  1. Identification of clinical spectrum of the disease in families

    Time frame: through study completion- approximately 6-12 months

    Genetic and clinical analysis reveals clinical features not previously assigned to the disease

Study contacts

Contact information is provided by the study sponsor or research team.

Patricia L Dahia, MD, PhD

CONTACT

[email protected]

210-567-4866

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center at San Antonio

Other

Registry information

Important dates

Study start
2026
Primary completion
2030
Study completion
2035
First posted
Nov 6, 2020
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.